Clinical trial · Expanded Access
Expanded Access to Nivolumab (Opdivo)
NCT03126643CI-TRIAL-00055275approved for marketingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Nivolumab in pediatric patients exhibiting a high mutational load.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Biological | Nivolumab | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 17 Years
Show eligibility criteria text
Specific eligibility criteria must be met for access outside of a clinical trial. These inclusion criteria include: * The illness must be serious or life threatening * There are no other viable options (including approved products or active clinical trials) * There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time * Other defined inclusion/exclusion criteria could be applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.